Top

Published in:

01-02-2022 | Hepatitis B | Clinical study

TNF-α inhibitors increase risk of HBV reactivation if HBsAg-positive

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Treatment of psoriasis (PsO) with tumour necrosis factor-alpha (TNF-α) inhibitors in patients who are hepatitis B surface antigen (HBsAg)-positive increases the risk of hepatitis B virus (HBV) reactivation unless the patients receive antiviral prophylaxis, according to findings of a systematic review and meta-analysis published in Dermatology and Therapy. …

Wang X, et al. Risk for Hepatitis B Virus Reactivation in Patients with Psoriasis Treated with Biological Agents: A Systematic Review and Meta-Analysis Dermatology and Therapy : 29 Jan 2022. Available from: URL: https://doi.org/10.1007/s13555-022-00682-5

Title: TNF-α inhibitors increase risk of HBV reactivation if HBsAg-positive
Publication date: 01-02-2022
Publisher: Springer International Publishing
Keywords: Hepatitis B
Vulgar Psoriasis
Psoriatic Arthritis
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-09552-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

TNF-α inhibitors increase risk of HBV reactivation if HBsAg-positive

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Ciclosporin/methotrexate

Phenytoin

Elasomeran

Belantamab-mafodotin

Multiple drugs

Ibrutinib/rituximab